Sanofi (NASDAQ:SNY) Receives Consensus Rating of “Hold” from Analysts

Sanofi (NASDAQ:SNY) has been assigned a consensus rating of “Hold” from the fourteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $54.00.

Several brokerages have recently issued reports on SNY. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Strong Q1 results: Sanofi beat consensus on both EPS and revenue (reported $2.18 EPS vs. $0.93 est.; revenue ~ $13.0B), driven by Dupixent and new launches, supporting an upbeat 2026 outlook. Sanofi’s first-quarter earnings edges past estimates
• Positive Sentiment: U.S. approval expansion for Dupixent: FDA cleared Dupixent as the first biologic for young children (2–11) with uncontrolled chronic spontaneous urticaria — supports future addressable market and long-term growth of a core franchise. Dupixent approved in the US for young children with uncontrolled CSU
• Positive Sentiment: CHMP recommends Cenrifki (tolebrutinib) for EU approval to treat secondary progressive MS without relapses — regulatory progress that could broaden neurology portfolio. CHMP recommends Cenrifki (tolebrutinib)
• Positive Sentiment: Label expansion wins: FDA expanded Tzield for pediatric use, adding another growth pathway in specialty medicines. Tzield gets FDA nod for kids
• Neutral Sentiment: €2.3 billion bond offering priced across 2029/2033/2037 tranches — proceeds earmarked for general corporate purposes; modestly increases debt but at market rates given Sanofi’s low leverage. Sanofi prices €2.3 billion bond offering
• Negative Sentiment: Sarclisa SC BLA delayed: FDA set a new decision date (July 2026) after a filing delay — pushes potential commercialization timeline and may defer expected revenues from that subcutaneous formulation. Sarclisa SC BLA faces delay

Sanofi Stock Down 1.6%

Shares of SNY stock opened at $46.78 on Friday. The stock has a market cap of $114.10 billion, a P/E ratio of 13.07, a PEG ratio of 1.18 and a beta of 0.42. Sanofi has a 52 week low of $43.32 and a 52 week high of $55.73. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The company’s fifty day simple moving average is $46.42 and its two-hundred day simple moving average is $47.98.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be paid a $2.4225 dividend. This represents a dividend yield of 502.0%. The ex-dividend date of this dividend is Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio is 44.44%.

Institutional Trading of Sanofi

Several hedge funds have recently made changes to their positions in the business. Advisory Services Network LLC raised its stake in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after buying an additional 210 shares in the last quarter. Waterfront Wealth Inc. boosted its position in shares of Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after acquiring an additional 214 shares in the last quarter. Savant Capital LLC increased its holdings in shares of Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after acquiring an additional 225 shares during the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of Sanofi by 2.3% in the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after acquiring an additional 226 shares during the last quarter. Finally, Wesbanco Bank Inc. raised its position in shares of Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after acquiring an additional 230 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.